Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

Corcept Therapeutics Incorporated (CORT) announced that the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with Cushing's syndrome, met its primary endpoint. Shares of the company were up 14.9% on May 28 following the announcement of the news. Treatment with relacorilant was well-tolerated in both phases of the GRACE study. The GRACE study consisted of two parts — the open-label portion and the randomized withdrawal phase. The study has now me ...